Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease
about
G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRsRelationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal StudiesAmyloid β production is regulated by β2-adrenergic signaling-mediated post-translational modifications of the ryanodine receptor.p62 improves AD-like pathology by increasing autophagyNoradrenergic dysfunction in Alzheimer's disease.Beta 2-adrenergic receptor activation enhances neurogenesis in Alzheimer's disease mice.Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer's disease-like pathologies and cognitive deficits.Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.Dyrk1 inhibition improves Alzheimer's disease-like pathology.Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening.Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.Sex Differences in Healthspan Predict Lifespan in the 3xTg-AD Mouse Model of Alzheimer's Disease.Enriched environment enhances β-adrenergic signaling to prevent microglia inflammation by amyloid-βCellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer's Disease
P2860
Q26752403-C112B383-0D6E-4F83-9BA3-797665A18976Q28074637-6F192C00-5273-44AB-B050-AE0314788156Q33806103-C3F7ADB8-6F83-4501-8702-CFF5C04D485FQ33821175-39F982A9-BEC1-4678-878D-22F1E3358975Q35749478-33A0F3CA-4AB3-4A48-B159-C68D9F871652Q37425227-5973ABE0-0D90-4430-90B0-5CB9F96F5A46Q38718079-1D36983E-0055-4CC9-A861-3731E0A2978CQ39019439-9F86C8A9-ACA0-4C23-B821-ED6A577E01D3Q41628814-1E91C95F-3F5A-4CF5-8872-D729F755DAF5Q42376445-8E9DA29B-E69A-4FD4-9388-AD6FBB9F3393Q47110701-BEF9B079-D13E-48E1-9588-EE3CB0576B7FQ47784892-74506DA6-5491-49CA-99E0-27043F003619Q48488584-71875832-4A17-411B-8DB0-4F9D088937C0Q55365674-F1FF09BB-686D-4BCE-B163-25F4A8A073F2Q57464744-CDD0CCD5-8E93-424E-B161-0802468395EBQ57779647-5E0382BD-2411-48D0-8394-EAE8111EC806
P2860
Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Administration of a selective ...... e model of Alzheimer's disease
@ast
Administration of a selective ...... e model of Alzheimer's disease
@en
Administration of a selective ...... e model of Alzheimer's disease
@nl
type
label
Administration of a selective ...... e model of Alzheimer's disease
@ast
Administration of a selective ...... e model of Alzheimer's disease
@en
Administration of a selective ...... e model of Alzheimer's disease
@nl
prefLabel
Administration of a selective ...... e model of Alzheimer's disease
@ast
Administration of a selective ...... e model of Alzheimer's disease
@en
Administration of a selective ...... e model of Alzheimer's disease
@nl
P2093
P2860
P3181
P1476
Administration of a selective ...... e model of Alzheimer's disease
@en
P2093
Antonella Caccamo
Caterina Branca
Elena V Wisely
Lauren K Hartman
Salvatore Oddo
P2860
P304
P3181
P356
10.1016/J.NEUROBIOLAGING.2014.06.011
P407
P577
2014-06-16T00:00:00Z